Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma

Inclusion Criteria: * patient with a NSCLC, non-resected, non-metastatic including a parenchyma portion * Age \>= 18 years * PS \<=2 * CT-scan within 3 months at inclusion * PET-scan within 3 months at inclusion * Respiratory functional exploration within 3 months at inclusion * estimated V20 (by radiotherapist)\< 35% on conventional pre-radiotherapy imaging * Tumor T0 to T4, M0; N1, N2 ou N3 by isolateral supra-clavicular involvement * Measurable disease according to RECIST criteria 1.1 * Curative intent Chest conventional radiation therapy * Radiation indication validated by a multidisciplinary meeting * Adequate contraceptive method for the whole study duration and for up to 28 days after the end of radiation * Mandatory affiliation with a health insurance company * Patients must provide dated \& written consent Exclusion Criteria: * Prior surgery for NSCLC * NSCLC nearby pulmonary apex or strictly intra-thoracic with no intra-parenchyma portion * Metastatic disease or N3 contralateral lymph node * History of chest irradiation * History of known increased intrinsic radiosensibility * Hypersensibility to active substance or excipient of fluoro-deoxyglucose-18F * Life expectancy \< 6 months * Patient with a concurrent malignancy or with a history of malignancy (excepted adequately treated basal cell skin carcinoma or cervical squamous cell carcinoma or other malignancies free of the disease for at least 5 years) * Pregnant or breastfeeding women * Psychological, sociological or geographical conditions that would limit compliance with study requirements * Patient deprived of freedom * Patient has concomitant participation to an other investigational study